

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



撥康視云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO GRANT OF RESTRICTED SHARE UNITS
UNDER THE POST-IPO SHARE INCENTIVE SCHEME**

Reference is made to the announcement (“the **Announcement**”) of Cloudbreak Pharma Inc. (“the **Company**”, and together with its subsidiaries, the “**Group**”) dated 16 January 2026 in relation to, among other things, grant of Restricted Share Units (“**RSUs**”) under the Post-IPO share incentive scheme. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

INFORMATION OF WHITCUP LIFE SCIENCES LLC

The Service Provider Participant, Whitcup Life Sciences LLC is wholly-owned by Dr. Scott Whitcup.

Whitcup Life Sciences LLC, is a consultant which provides research and development services, business development services, and/or other professional services to the Group where the continuity and frequency of such services is akin to that of our employees. Dr. Scott Whitcup is the chairman of the Company’s scientific advisory board. Whitcup Life Sciences LLC is not a Director, a chief executive, or a substantial shareholder of the Company, or an associate of any of them.

Whitcup Life Sciences LLC is responsible for providing guidance on clinical research protocols across multiple company projects and assist the company in communication with the United States Food and Drug Administration (the “**FDA**”). Some of the projects conducted by Whitcup Life Sciences LLC are set forth below:

- CBT-001: provide guidance on Multi-Regional Clinical Trials Phase 3 clinical study design and discussion with the FDA on the Special Protocol Agreement in the United States and China;

- CBT-004: provide guidance on the End-of-the-Phase 2 meeting with the FDA towards the development of approval endpoints for Phase 3 trials and New Drug Approval requirement in the United States;
- Other programs such as CBT-199 for presbyopia towards Investigational New Drug application in the United States; and
- Other business development: provide support to ongoing business development for CBT-001, CBT-004 and CBT-199 with potential strategies.

VESTING PERIOD OF THE RSUs

The RSUs shall vest (in whole or in part, as applicable) if and to the extent that both the relevant continuous service condition and the performance target are satisfied on or prior to the expiration date (i.e. 30 September 2032).

Whitcup Life Sciences LLC shall satisfy the continuous service condition as to one-fifth of the RSUs on each of the first five anniversaries of the grant date (the “**Grant Date**”) (i.e. 16 January 2026), provided Whitcup Life Sciences LLC remain in service (the “**Service**”) from the Grant Date through the relevant service date.

The Service refers to the periods of time in which (i) Whitcup Life Sciences LLC is engaged under a consulting agreement with the Group, or (ii) Scott Whitcup is providing services to the Group directly as a consultant, employee or other service provider.

None of the vesting period of the aforesaid 3,000,000 RSUs granted is less than 12 months after the Grant Date.

PERFORMANCE TARGET OF THE RSUs

The performance target shall be achieved, in whole or in part, from time to time, based on the Group signing of one or more business development agreements. The performance target shall be satisfied with respect to all 3,000,000 RSUs upon the signing of one or more business development deals totaling US\$100,000,000 in combined upfront payments and potential milestone payments. If at any time signed business development agreements have less than US\$100,000,000 in combined upfront payments and potential milestone payments, (i) the performance target shall be satisfied at such time on a pro-rata basis based on the percentage of the US\$100,000,000 target that is then attained, and (ii) the performance target can be achieved with respect to the remaining portion of the 3,000,000 RSUs if and when additional business development deals are signed.

The information provided in this announcement does not affect other information contained in the Announcement. Save as disclosed above, the contents of the Announcement remain unchanged.

By order of the Board
Cloudbreak Pharma Inc.

Dr. NI Jinsong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 22 January 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter and Mr. Lee Alex Jao Jang as independent non-executive directors.

* *For identification purpose only*